Cargando…
Periprocedural Hydrogen Sulfide Therapy Improves Vascular Remodeling and Attenuates Vein Graft Disease
BACKGROUND: Failure rates after revascularization surgery remain high, both in vein grafts (VG) and arterial interventions. One promising approach to improve outcomes is endogenous upregulation of the gaseous transmitter‐molecule hydrogen sulfide, via short‐term dietary restriction. However, strict...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7763704/ https://www.ncbi.nlm.nih.gov/pubmed/33146045 http://dx.doi.org/10.1161/JAHA.120.016391 |
_version_ | 1783628081538269184 |
---|---|
author | Kip, Peter Tao, Ming Trocha, Kaspar M. MacArthur, Michael R. Peters, Hendrika A. B. Mitchell, Sarah J. Mann, Charlotte G. Sluiter, Thijs J. Jung, Jonathan Patterson, Suzannah Quax, Paul H. A. de Vries, Margreet R. Mitchell, James R. Keith Ozaki, C. |
author_facet | Kip, Peter Tao, Ming Trocha, Kaspar M. MacArthur, Michael R. Peters, Hendrika A. B. Mitchell, Sarah J. Mann, Charlotte G. Sluiter, Thijs J. Jung, Jonathan Patterson, Suzannah Quax, Paul H. A. de Vries, Margreet R. Mitchell, James R. Keith Ozaki, C. |
author_sort | Kip, Peter |
collection | PubMed |
description | BACKGROUND: Failure rates after revascularization surgery remain high, both in vein grafts (VG) and arterial interventions. One promising approach to improve outcomes is endogenous upregulation of the gaseous transmitter‐molecule hydrogen sulfide, via short‐term dietary restriction. However, strict patient compliance stands as a potential translational barrier in the vascular surgery patient population. Here we present a new therapeutic approach, via a locally applicable gel containing the hydrogen sulfide releasing prodrug (GYY), to both mitigate graft failure and improve arterial remodeling. METHODS AND RESULTS: All experiments were performed on C57BL/6 (male, 12 weeks old) mice. VG surgery was performed by grafting a donor‐mouse cava vein into the right common carotid artery of a recipient via an end‐to‐end anastomosis. In separate experiments arterial intimal hyperplasia was assayed via a right common carotid artery focal stenosis model. All mice were harvested at postoperative day 28 and artery/graft was processed for histology. Efficacy of hydrogen sulfide was first tested via GYY supplementation of drinking water either 1 week before VG surgery (pre‐GYY) or starting immediately postoperatively (post‐GYY). Pre‐GYY mice had a 36.5% decrease in intimal/media+adventitia area ratio compared with controls. GYY in a 40% Pluronic gel (or vehicle) locally applied to the graft/artery had decreased intimal/media area ratios (right common carotid artery) and improved vessel diameters. GYY‐geltreated VG had larger diameters at both postoperative days 14 and 28, and a 56.7% reduction in intimal/media+adventitia area ratios. Intimal vascular smooth muscle cell migration was decreased 30.6% after GYY gel treatment, which was reproduced in vitro. CONCLUSIONS: Local gel‐based treatment with the hydrogen sulfide‐donor GYY stands as a translatable therapy to improve VG durability and arterial remodeling after injury. |
format | Online Article Text |
id | pubmed-7763704 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-77637042020-12-28 Periprocedural Hydrogen Sulfide Therapy Improves Vascular Remodeling and Attenuates Vein Graft Disease Kip, Peter Tao, Ming Trocha, Kaspar M. MacArthur, Michael R. Peters, Hendrika A. B. Mitchell, Sarah J. Mann, Charlotte G. Sluiter, Thijs J. Jung, Jonathan Patterson, Suzannah Quax, Paul H. A. de Vries, Margreet R. Mitchell, James R. Keith Ozaki, C. J Am Heart Assoc Original Research BACKGROUND: Failure rates after revascularization surgery remain high, both in vein grafts (VG) and arterial interventions. One promising approach to improve outcomes is endogenous upregulation of the gaseous transmitter‐molecule hydrogen sulfide, via short‐term dietary restriction. However, strict patient compliance stands as a potential translational barrier in the vascular surgery patient population. Here we present a new therapeutic approach, via a locally applicable gel containing the hydrogen sulfide releasing prodrug (GYY), to both mitigate graft failure and improve arterial remodeling. METHODS AND RESULTS: All experiments were performed on C57BL/6 (male, 12 weeks old) mice. VG surgery was performed by grafting a donor‐mouse cava vein into the right common carotid artery of a recipient via an end‐to‐end anastomosis. In separate experiments arterial intimal hyperplasia was assayed via a right common carotid artery focal stenosis model. All mice were harvested at postoperative day 28 and artery/graft was processed for histology. Efficacy of hydrogen sulfide was first tested via GYY supplementation of drinking water either 1 week before VG surgery (pre‐GYY) or starting immediately postoperatively (post‐GYY). Pre‐GYY mice had a 36.5% decrease in intimal/media+adventitia area ratio compared with controls. GYY in a 40% Pluronic gel (or vehicle) locally applied to the graft/artery had decreased intimal/media area ratios (right common carotid artery) and improved vessel diameters. GYY‐geltreated VG had larger diameters at both postoperative days 14 and 28, and a 56.7% reduction in intimal/media+adventitia area ratios. Intimal vascular smooth muscle cell migration was decreased 30.6% after GYY gel treatment, which was reproduced in vitro. CONCLUSIONS: Local gel‐based treatment with the hydrogen sulfide‐donor GYY stands as a translatable therapy to improve VG durability and arterial remodeling after injury. John Wiley and Sons Inc. 2020-11-04 /pmc/articles/PMC7763704/ /pubmed/33146045 http://dx.doi.org/10.1161/JAHA.120.016391 Text en © 2020 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Research Kip, Peter Tao, Ming Trocha, Kaspar M. MacArthur, Michael R. Peters, Hendrika A. B. Mitchell, Sarah J. Mann, Charlotte G. Sluiter, Thijs J. Jung, Jonathan Patterson, Suzannah Quax, Paul H. A. de Vries, Margreet R. Mitchell, James R. Keith Ozaki, C. Periprocedural Hydrogen Sulfide Therapy Improves Vascular Remodeling and Attenuates Vein Graft Disease |
title | Periprocedural Hydrogen Sulfide Therapy Improves Vascular Remodeling and Attenuates Vein Graft Disease |
title_full | Periprocedural Hydrogen Sulfide Therapy Improves Vascular Remodeling and Attenuates Vein Graft Disease |
title_fullStr | Periprocedural Hydrogen Sulfide Therapy Improves Vascular Remodeling and Attenuates Vein Graft Disease |
title_full_unstemmed | Periprocedural Hydrogen Sulfide Therapy Improves Vascular Remodeling and Attenuates Vein Graft Disease |
title_short | Periprocedural Hydrogen Sulfide Therapy Improves Vascular Remodeling and Attenuates Vein Graft Disease |
title_sort | periprocedural hydrogen sulfide therapy improves vascular remodeling and attenuates vein graft disease |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7763704/ https://www.ncbi.nlm.nih.gov/pubmed/33146045 http://dx.doi.org/10.1161/JAHA.120.016391 |
work_keys_str_mv | AT kippeter periproceduralhydrogensulfidetherapyimprovesvascularremodelingandattenuatesveingraftdisease AT taoming periproceduralhydrogensulfidetherapyimprovesvascularremodelingandattenuatesveingraftdisease AT trochakasparm periproceduralhydrogensulfidetherapyimprovesvascularremodelingandattenuatesveingraftdisease AT macarthurmichaelr periproceduralhydrogensulfidetherapyimprovesvascularremodelingandattenuatesveingraftdisease AT petershendrikaab periproceduralhydrogensulfidetherapyimprovesvascularremodelingandattenuatesveingraftdisease AT mitchellsarahj periproceduralhydrogensulfidetherapyimprovesvascularremodelingandattenuatesveingraftdisease AT manncharlotteg periproceduralhydrogensulfidetherapyimprovesvascularremodelingandattenuatesveingraftdisease AT sluiterthijsj periproceduralhydrogensulfidetherapyimprovesvascularremodelingandattenuatesveingraftdisease AT jungjonathan periproceduralhydrogensulfidetherapyimprovesvascularremodelingandattenuatesveingraftdisease AT pattersonsuzannah periproceduralhydrogensulfidetherapyimprovesvascularremodelingandattenuatesveingraftdisease AT quaxpaulha periproceduralhydrogensulfidetherapyimprovesvascularremodelingandattenuatesveingraftdisease AT devriesmargreetr periproceduralhydrogensulfidetherapyimprovesvascularremodelingandattenuatesveingraftdisease AT mitchelljamesr periproceduralhydrogensulfidetherapyimprovesvascularremodelingandattenuatesveingraftdisease AT keithozakic periproceduralhydrogensulfidetherapyimprovesvascularremodelingandattenuatesveingraftdisease |